CXCR3 and acute myeloid leukemia: This phenomenon is consistent with the observation that ERK signaling can be reactivated in FLT3/ITD + AML cells treated with TKIs,8 and it supports the notion that CXCR3 is, at least partially, responsible for the TKI-induced changes in signaling (Fig. 6a–c).